NCT07530744 2026-04-15
Cronos
Elisabethinen Hospital
Phase NA Not yet recruiting
Clinical Trials
133 trialsNCT06865339 2026-04-13
TRIPL
Montefiore Medical Center
Phase 2 Recruiting
NCT03606070 2026-03-23
IMAHTEP
Gustave Roussy, Cancer Campus, Grand Paris
Phase NA Terminated
NCT06738160 2026-03-20
The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
Fudan University
Phase 2 Recruiting
NCT05798845 2026-03-11
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Recruiting
NCT05636267 2026-03-09
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
Akeso
Phase 1/2 Terminated
NCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT05378763 2026-02-18
PINNACLE
Spectrum Pharmaceuticals, Inc
Phase 3 Suspended
NCT07413952 2026-02-17
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Not yet recruiting
NCT05714891 2026-02-12
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT07082179 2026-02-11
A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital
Phase 2 Recruiting
NCT07376382 2026-02-02
SYNSTAR-02
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 3 Not yet recruiting
NCT07379398 2026-01-30
Iparomlimab and Tuvonralimab Injection Combined With SBRT in Patients With Early-Stage Non-Small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07358689 2026-01-22
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06576635 2026-01-20
LUNG-05
University of Illinois at Chicago
Phase NA Recruiting
NCT05089916 2026-01-14
ROSE
AIO-Studien-gGmbH
Phase 2 Active not recruiting
NCT07330037 2026-01-09
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Recruiting
NCT07169552 2025-12-17
HC010 in First-line PD-L1 Positive Advanced NSCLC Patients
HC Biopharma Inc.
Phase 2 Recruiting
NCT07281209 2025-12-15
A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer
Shanghai Chest Hospital
Phase 2 Not yet recruiting
NCT07247227 2025-11-25
Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC
Peking Union Medical College
Phase NA Recruiting
NCT04858958 2025-11-19
FAVOUR
Allist Pharmaceuticals, Inc.
Phase 1 Active not recruiting
NCT05466149 2025-11-19
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Allist Pharmaceuticals, Inc.
Phase 2 Active not recruiting
NCT07181499 2025-09-30
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
Betta Pharmaceuticals Co., Ltd.
Phase 2 Recruiting
NCT07198217 2025-09-30
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
Zibo Municipal Hospital
Phase 2 Recruiting
NCT06448910 2025-09-24
Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC
Fudan University
Phase 2 Active not recruiting
NCT07156604 2025-09-05
Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Fudan University
Phase 2 Not yet recruiting
NCT07153770 2025-09-04
Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Not yet recruiting
NCT05773092 2025-09-03
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC
National Cancer Centre, Singapore
Phase 2 Active not recruiting
NCT07134413 2025-08-21
QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC
Guangdong Association of Clinical Trials
Phase 2 Not yet recruiting
NCT05078931 2025-07-30
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients
Shanghai Chest Hospital
Phase 2 Active not recruiting
NCT07089199 2025-07-28
TitAN
Qilu Hospital of Shandong University
Phase 2 Not yet recruiting
NCT06864624 2025-07-25
WU-KONG20
Tang-Du Hospital
Phase 2 Recruiting
NCT07085182 2025-07-25
Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study
Zibo Municipal Hospital
Phase 2 Recruiting
NCT07086326 2025-07-25
NEOINSPIRE
Peking University People's Hospital
Phase 2 Not yet recruiting
NCT06754644 2025-06-10
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT04820023 2025-06-06
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Bridge Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT06940401 2025-05-14
JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations
Suzhou Junjing BioSciences Co., Ltd.
Phase 1/2 Recruiting
NCT05994131 2025-04-30
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
InxMed (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06944470 2025-04-25
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Not yet recruiting
NCT02973763 2025-04-03
Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 1 Terminated
NCT06457789 2025-04-02
iRelate
Amsterdam UMC, location VUmc
Phase NA Recruiting
NCT06893354 2025-03-25
Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics
The First Affiliated Hospital of Guangzhou Medical University
Phase 4 Not yet recruiting
NCT04958967 2025-03-14
Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation
Allist Pharmaceuticals, Inc.
Phase 1 Withdrawn
NCT05058560 2025-03-13
Tislelizumab in Addition to BACE in Patients with NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
NCT06714708 2025-02-10
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
Anhui Provincial Cancer Hospital
Phase 2 Recruiting
NCT06672068 2024-12-30
A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC
TYK Medicines, Inc
Phase 2 Not yet recruiting
NCT06746870 2024-12-24
A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 2 Not yet recruiting
NCT06532591 2024-12-20
Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Recruiting
NCT06739031 2024-12-18
Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors
Energenx Medical LTD.
Phase NA Not yet recruiting
NCT06735508 2024-12-16
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
Guangdong Provincial People's Hospital
Phase EARLY_PHASE1 Not yet recruiting